摘要
目的观察放化疗治疗中晚期食管癌患者的临床效果及不良反应。方法选择2013年12月-2014年9月中晚期非手术食管癌患者56例,随机分为观察组与对照组各28例。对照组予X线直线加速器照射放射治疗;治疗组在放射治疗基础上给予紫杉醇及奈达铂化疗。随访6~24个月,比较2组临床疗效、近期不良反应、1年生存率。结果观察组近期总有效率为78.6%明显高于对照组的57.1%（P〈0.05）。观察组1年生存率为92.8%（26/28）明显高于对照组的64.3%（18/28）（P〈0.05）。2组不良反应主要为放射性食管炎,骨髓抑制、胃肠道反应、血液毒性反应等,以1~2级不良反应为主。观察组1~2级不良反应发生率为高于对照组,而3~4级不良反应发生率低于对照组,差异均有统计学意义（P〈0.01）。结论同步放化疗对中晚期食管癌患者的临床效果好,不良反应少,可提高短期生存率,值得临床推广应用。
Objective To observe the clinical effect of patients with radiation and chemotherapy treatment patients and adverse reactions. Methods 56 cases of esophageal carcinoma in middle and late stage were randomly divided into observation group and control group with 28 cases in each group. Patients in control group were treated with ray linear accelerator radiation therapy; treatment group in radiotherapy based on given paclitaxel and nedaplatin chemotherapy. Follow up for 6 to 24 months,the clinical efficacy,adverse reactions,1 year survival rate were compared between the 2 groups. Results The total effective rate of the observation group was 57. 1%,which was significantly higher than that of the control group. The difference was statistically significant（ P〈0. 05）. The 1 year survival rate in the observation group was 92. 8%（ 26 /28） was significantly higher than that in the control group（ 28 /18）,the difference between the 2 groups was statistically significant（ P〈0. 05）.The main adverse reactions of the 2 groups were radioactive esophagitis,bone marrow suppression,gastrointestinal reaction,and blood toxicity,etc. The incidence of adverse reactions in the observation group was higher than that in the control group at 1 to2 levels,and the incidence of adverse reactions in the 3 to 4 levels was lower than that in the control group（ P〈0. 01）. Conclusion patients with chemoradiation for patients with clinical effect is good,less adverse reaction,can improve the short-term survival rate,worthy of clinical promotion.
出处
《临床合理用药杂志》
2015年第20期24-25,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
食管癌
中晚期
放射治疗
化疗
不良反应
esophageal cancer
middle-late
Radiation therapy
Chemotherapy
Adverse reactions
